Molecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Molecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran; Department of Neurosciences- DNS, University of Padua, Padua, Italy.
Pathol Res Pract. 2021 Apr;220:153396. doi: 10.1016/j.prp.2021.153396. Epub 2021 Mar 1.
Recent studies have shown that the histone deacetylase-8 (HDAC8), as one of the HDACs, regulates the expression and activity of various genes involved in cancer initiation and progression. The HDAC8 plays an epigenetic role to dysregulate expressions or to interact with transcription factors. Most researchers had focused on the HDAC 1-3 and 6, but today the HDAC8 isotype is a promising target in cancer therapy. Different studies, on breast cancer (BC) cells, have recently shown the HDAC8 overexpression and suggested its oncogenic potential. It seems that the HDAC8 could be a novel and promising target in breast cancer treatment. Some studies on BC demonstrated therapeutic properties of the inhibitors of HDAC8 such as suberoylanilide hydroxamic acid (SAHA), Trichostatin A, valproic acid, sodium butyrate, 1,3,4 oxadiazole with alanine hybrid [(R)-2-amino-N-((5-phenyl-1,3,4-oxadiazol-2-yl) methyl) propanamide (10b)], N-(2-Hydroxyphenyl)-2propylpentanamide (compound 2) and PCI-34051. In this review, we highlight the role and existing inhibitors of HDAC8 in BC pathogenesis and therapy.
最近的研究表明，组蛋白去乙酰化酶-8（HDAC8）作为 HDAC 之一，调节涉及癌症发生和进展的各种基因的表达和活性。HDAC8 发挥表观遗传作用，失调表达或与转录因子相互作用。大多数研究人员专注于 HDAC 1-3 和 6，但如今 HDAC8 同工酶是癌症治疗中有前途的靶点。最近的一些研究表明，乳腺癌（BC）细胞中 HDAC8 过表达，并提示其致癌潜能。似乎 HDAC8 可以成为乳腺癌治疗中的一个新的有前途的靶点。一些关于 BC 的研究表明，HDAC8 的抑制剂具有治疗特性，如丙戊酸、丁酸钠、1,3,4 恶二唑与丙氨酸杂合 [(R)-2-氨基-N-((5-苯基-1,3,4-恶二唑-2-基)甲基)丙酰胺 (10b)]、N-(2-羟基苯基)-2 丙基戊酰胺（化合物 2）和 PCI-34051。在这篇综述中，我们强调了 HDAC8 在 BC 发病机制和治疗中的作用和现有的抑制剂。
